Stavrianna Diavati , Marios Sagris *, Dimitrios Terentes-Printzios and Charalambos Vlachopoulos
Venous thromboembolism (VTE), clinically presenting as deep-vein thrombosis (DVT) or pulmonary embolism (PE), constitutes a major global healthcare concern with severe complications, long-term morbidity and mortality. Although several clinical, genetic and acquired risk factors for VTE have been identified, the molecular pathophysiology and mechanisms of disease progression remain poorly understood. Anticoagulation has been the cornerstone of therapy for decades, but there still are uncertainties regarding primary and secondary VTE prevention, as well as optimal therapy duration. In this review we discuss the role of factor Xa in coagulation cascade and the different choices of anticoagulation therapy based on patients’ predisposing risk factors and risk of event recurrence. Further, we compare newer agents to traditional anticoagulation treatment, based on most recent studies and guidelines.
Venous thromboembolism, Deep vein thrombosis, pulmonary embolism, treatment; options, duration, direct oral anticoagulants
Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, General Hospital of Nikaia, Piraeus, Athens, Oxford Heart Centre, NIHR Biomedical Research Centre, Oxford University Hospitals, Oxford, First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens